Focus Stocks

Hewlett Packard (HPQ)

Hewlett Packard (HPQ)


Dell (DELL)

Dell (DELL)


Facebook (FB)

Facebook (FB)


Apple (AAPL)

Apple (AAPL)


Goldman Sachs (GS)

Goldman Sachs (GS)


Featured Stories

Fred's First Quarter 2012 EPS Increase 17%

Fred's First Quarter 2012 EPS Increase 17%


Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook

Newell Rubbermaid to Reaffirm Fiscal Year 2012 Outlook


Best ETFs For Facebook Exposure

Best ETFs For Facebook Exposure


McDonald's Announces Quarterly Cash Dividend

McDonald's Announces Quarterly Cash Dividend


Is KB HOME Closing in to Resistance?

Is KB HOME Closing in to Resistance?


Cerus to Present at the 14th Annual BIO CEO & Investor Conference on February 13, 2012

CONCORD, Calif.-( Business Wire )-

Cerus Corporation (NASDAQ:CERS) announced today that William “Obi” Greenman, president and chief executive officer, is scheduled to present a corporate update at the 14th Annual BIO CEO & Investor Conference in New York at 10:30 AM ET on Monday, February 13, 2012.

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at http://investor.cerus.com. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See http://www.cerus.com for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Cerus CorporationLainie Corten, 925-288-6319Director, Global Communications & Marketing

TradersHuddle Search

Sponsored By:

Stock Search:


Site Search:

Loading

Copyright © 2011 TradersHuddle.com. All Rights Reserved.